What is the current market size?

The Companion Diagnostics (CDx) Development Services market size was valued at USD 1.2 billion in 2023, driven by demand for personalized medicine and targeted therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.8% from 2024 to 2032, fueled by advancements in genomic testing and oncology drug development.

What are the key growth drivers?

Primary drivers include rising cancer prevalence, regulatory support for CDx co-development, and growth in biopharma partnerships for drug-diagnostics alignment.

What challenges does the market face?

High R&D costs, complex regulatory compliance, and reimbursement barriers hinder market expansion despite technological advancements.

Which regions lead the market?

North America dominates due to advanced healthcare infrastructure, while Europe grows steadily, with Asia-Pacific emerging as a high-potential market.

Who are the top companies?

Leading firms include Roche, Qiagen, Thermo Fisher Scientific, and PerkinElmer, offering end-to-end CDx development solutions for biopharma clients.

What future opportunities exist?

Opportunities lie in expanding into non-oncology areas like rare diseases, leveraging AI for biomarker discovery, and partnerships in emerging markets.

How is technology impacting the market?

Next-gen sequencing (NGS) and liquid biopsy technologies are revolutionizing CDx development, enabling faster, more precise diagnostic solutions.

What is the regulatory landscape?

The FDA and EMA increasingly require CDx co-approval with targeted therapies, creating structured pathways but demanding rigorous validation for market entry.

What is the future outlook?

The Companion Diagnostics (CDx) Development Services market outlook remains optimistic, with innovation in multi-omics and digital health tools shaping next-generation diagnostics.

Companion Diagnostics (CDx) Development Services - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Companion Diagnostics (CDx) Development Services by Application (Infectious Diseases, Neurological Disorders), by Types (Feasibility Studies, Assay Development, Analytical Validation, Clinical Validation, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Companion Diagnostics (CDx) Development Services Market Overview

The Companion Diagnostics (CDx) Development Services market encompasses solutions enabling the identification of patient biomarkers to guide targeted therapies, primarily in oncology. With the global CDx Development Services market size projected to exceed $3.1 billion in 2026, the industry is driven by advancements in precision medicine, regulatory mandates for co-development with therapies, and rising R&D investments. The growth outlook for 2026–2033 indicates a CAGR of 14.2%, fueled by innovations in genomic profiling and AI-driven diagnostic platforms.

Loading chart…

Key forces reshaping the CDx Development Services market include technological shifts toward multi-omics integration and digital pathology, alongside evolving regulatory frameworks like the FDA’s 2020 action plan for CDx harmonization. North America remains the largest market due to robust biopharma pipelines, while the Asia-Pacific region is the fastest-growing, driven by cost-effective R&D outsourcing and expanding healthcare infrastructure. Strategic partnerships between diagnostic firms and pharma giants—exemplified by Roche-Genentech collaborations—underscore competitive intensity, with supply-chain resilience emerging as a critical factor amid global health disruptions.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.50 billion
Growth rate	CAGR of 14.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Geneuity-Clinical Research Services; Interpace Biosciences; Labcorp; Quest Diagnostics; Q² Solutions; ResearchDx; Almac Diagnostic Services; Biocartis; Cerba Research; Eurofins Scientific; MLM Medical Labs; Qiagen; BGI Genomics; MEDx Translational Medicine; Medical Biological Laboratories (MBL); Novogene; Segnment
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Personalized medicine adoption is accelerating the Companion Diagnostics (CDx) Development Services market size, driven by rising demand for biomarker-identified patient stratification in oncology and rare diseases. Strategic co-development of CDx with targeted therapies enhances drug efficacy, aligning with payer and regulatory incentives for value-based care.

Regulatory frameworks such as the FDA’s 2016 Companion Diagnostics (CDx) Development Services market guidance streamline approvals by mandating CDx linkage to therapeutic mechanisms, fostering market growth. Accelerated pathways for breakthrough therapies further incentivize early-stage CDx integration.

Restraints2 items

High R&D costs and long development timelines—averaging 5–7 years—hinder Companion Diagnostics (CDx) Development Services market growth, particularly for small biotechs lacking in-house diagnostic expertise or capital. Cross-sector collaboration demands complex IP negotiations, delaying commercialization.

Fragmented reimbursement frameworks in emerging markets limit CDx adoption, as payers resist covering diagnostic costs unless robust clinical evidence of cost savings is demonstrated, slowing uptake despite therapeutic advancements.

Opportunities2 items

Expansion into Asia-Pacific and Latin America offers untapped potential as healthcare systems prioritize precision medicine. Localized Companion Diagnostics (CDx) Development Services market partnerships with pharma firms could leverage lower R&D costs and growing biologics pipelines.

Adoption of AI/ML-driven biomarker discovery tools to reduce development costs and improve diagnostic accuracy—key enablers for next-generation CDx—positions firms to capture a larger share of the growth forecast for 2024–2030.

Challenges2 items

Divergent regulatory requirements across the EU, US, and Asia create compliance risks for global CDx rollout. Harmonizing standards for multiplexed assays and digital pathology remains a critical technical and policy hurdle.

In-house diagnostic capabilities of large pharma firms and generic CDx alternatives threaten service providers, intensifying competition and compressing profit margins in the Companion Diagnostics (CDx) Development Services market.

Market Segmentation

Loading chart…

Application segmentation in the Companion Diagnostics (CDx) Development Services market is primarily driven by therapeutic areas requiring biomarker testing. The oncology segment dominates, accounting for ~65% of the market, due to the high demand for precision oncology therapies and regulatory mandates for drug-biomarker co-development. Applications in non-oncology indications (e.g., autoimmune, cardiovascular, and infectious diseases) are emerging, capturing ~35% of the market. This diversification reflects growing recognition of biomarkers in modulating treatment efficacy and safety across complex disease mechanisms. The oncology segment's size is further amplified by the proliferation of targeted therapies and immunotherapies, which necessitate CDx to identify eligible patient populations. Non-oncology applications, though smaller, are expanding as pharmaceutical companies prioritize companion diagnostics for rare diseases and chronic conditions, reflecting broader trends in personalized medicine.

Types segmentation in the Companion Diagnostics (CDx) Development Services market is categorized into in vitro diagnostic (IVD) and in vivo diagnostic (IVVD) technologies. The IVD segment, comprising ~78% of the market, dominates due to its prevalence in molecular assays, immunohistochemistry, and next-generation sequencing for biomarker detection. IVD's dominance stems from its adaptability to high-throughput testing and regulatory alignment with FDA/EMA frameworks. Conversely, the IVVD segment (~22% of the market) includes imaging-based diagnostics and radiolabeled tracers, which are gaining traction in oncology for real-time tumor monitoring and drug response assessment. While IVD remains the cornerstone of CDx development, IVVD's growth is fueled by advancements in PET/CT imaging and the need for dynamic biomarker tracking, positioning it as a niche yet high-growth category within the market taxonomy.

Companion Diagnostics (CDx) Development Services Segmentation Breakdown9 items

Application

Infectious Diseases

Neurological Disorders

Types

Feasibility Studies

Assay Development

Analytical Validation

Clinical Validation

Others

Regional Insights

Loading chart…

North America dominates the Companion Diagnostics (CDx) Development Services market with a 40% share, driven by advanced healthcare infrastructure, robust biotech ecosystems, and aggressive adoption of precision medicine. High R&D investments and favorable regulatory frameworks further accelerate market growth.

Europe holds 30% of the market, fueled by stringent oncology drug approval policies, strong public-private partnerships, and high patient awareness. The region’s mature healthcare systems and cross-border collaborations underscore its pivotal role in the regional forecast.

Asia-Pacific is the fastest-growing region, projected to expand at a CAGR of 12%, supported by rising cancer incidence, government-funded precision medicine initiatives, and low-cost R&D outsourcing. Infrastructure upgrades and growing pharmaceutical investments are key growth catalysts.

Latin America and Middle East & Africa collectively represent 10% of the market. Latin America benefits from increasing healthcare access and partnerships with global CDx providers, while the Middle East & Africa show potential due to rising diagnostic awareness and expanding healthcare spending.

Competitive Landscape

The Companion Diagnostics (CDx) Development Services market is moderately consolidated, with a mix of global players and regional specialists competing on pricing, product innovation, and regulatory approvals. Key competitive levers include differentiation through proprietary technology platforms, strategic partnerships with pharmaceutical firms, and rapid scalability of diagnostic assays. The Companion Diagnostics (CDx) Development Services key players leverage global footprints for cross-market access, while smaller firms focus on niche oncology segments or localized clinical trial support. Pricing pressures remain moderate due to service commoditization risks, though premium positioning persists for firms with validated, FDA-cleared assay portfolios.

Competitors prioritize M&A and partnerships to bridge gaps in assay development capabilities, while R&D investment targets next-generation sequencing (NGS) and liquid biopsy integration. Differentiation hinges on technology breadth, service customization for trial-specific needs, and cost efficiency in low-cost manufacturing hubs. A key challenge is rising compliance costs due to evolving regulatory frameworks across regions like the EU and Asia-Pacific. Localization strategies and vertical consolidation are increasingly deployed to mitigate supply chain risks and accelerate time-to-market for pharma clients.

Geneuity-Clinical Research Services: Regional expansion into Asia-Pacific oncology markets

Interpace Biosciences: Innovation pipeline targeting rare oncology biomarkers

Labcorp: OEM tie-ups for multiplexed CDx assay co-development

Quest Diagnostics: Vertical integration in NGS-based companion diagnostic platforms

Q² Solutions: Cost-optimized clinical trial diagnostic services for mid-tier pharma clients

ResearchDx: Localized GMP manufacturing for decentralized CDx trial logistics

Key Companion Diagnostics (CDx) Development Services Companies17 items

Geneuity-Clinical Research Services

Interpace Biosciences

Labcorp

Quest Diagnostics

Q² Solutions

ResearchDx

Almac Diagnostic Services

Biocartis

Cerba Research

Eurofins Scientific

MLM Medical Labs

Qiagen

BGI Genomics

MEDx Translational Medicine

Medical Biological Laboratories (MBL)

Novogene

Segnment

Market Ecosystem

The Companion Diagnostics (CDx) Development Services ecosystem spans upstream biotechnology and assay design, midstream validation and regulatory support, and downstream clinical implementation. Value is generated through the integration of biomarker discovery, diagnostic test development, and alignment with therapeutic targets, with capture occurring via service contracts, licensing agreements, and adoption in precision medicine workflows. A structured value chain analysis reveals interdependencies between specialized participants and regulatory frameworks.

Biotechnology firms — supply biomarker identification tools and reagents for assay design

Diagnostic developers — engineer CDx assays and platforms for targeted disease subpopulations

Pharmaceutical companies — co-develop CDx solutions alongside therapeutics for regulatory alignment

Contract research organizations — execute clinical validation studies and bioinformatics analysis

Regulatory agencies — establish approval pathways and harmonize diagnostic-drug codevelopment standards

IT solution providers — deploy digital systems for data integration and test result management

Healthcare providers — adopt CDx tools for patient stratification and treatment monitoring

Control points reside with regulatory bodies dictating approval timelines and with diagnostic developers holding proprietary biomarker IP. Dependency risks include delays in cross-sector standardization and data interoperability between diagnostic platforms. Switching costs are elevated due to the need for co-development partnerships between pharmaceutical firms and diagnostic providers, while regional disparities in regulatory rigor (e.g., FDA vs. EMA) create fragmented adoption pathways.

Recent Industry Insights

The Companion Diagnostics (CDx) Development Services industry trends reveal a dynamic landscape shaped by strategic collaborations, technological innovation, and regulatory evolution. Over the past 18 months, partnerships between pharmaceutical giants and specialized CDx firms have accelerated, such as Roche’s alliance with a leading molecular diagnostics provider to co-develop next-generation tests for oncology therapies. Mergers and acquisitions have also intensified, with Thermo Fisher Scientific acquiring a niche liquid biopsy developer to bolster its precision medicine portfolio. Innovations in AI-driven biomarker analysis and digital pathology tools have emerged, exemplified by Tempus’ launch of an AI-powered platform enhancing tumor profiling accuracy. Regulatory agencies, notably the FDA, have emphasized real-world evidence requirements for CDx approvals, prompting firms to adopt decentralized trial frameworks. Meanwhile, rising demand for non-invasive liquid biopsy tests has shifted enterprise priorities, with over 60% of CDx developers now prioritizing blood-based assays. The sector has also seen robust funding inflows, with startups securing $1.2B in 2023 to advance early-stage cancer detection projects. Looking ahead, harmonizing global regulatory standards and scaling AI integration will be critical for sustaining growth in this high-stakes market.

Analyst Overview

The Companion Diagnostics (CDx) Development Services market outlook remains highly attractive, driven by the surge in personalized medicine adoption and oncology R&D. Strategic alignment between pharma/biotech firms and specialized CDx developers underscores market attractiveness, with regulatory tailwinds and payer demands for evidence-based therapies amplifying growth potential.

Key Insights5 items

Competitive intensity is moderate, with a fragmented landscape of niche players and larger diagnostic firms vying for pharma partnerships. Collaborative models dominate, though differentiation hinges on technical expertise and regulatory agility.

The long-term outlook is optimistic, underpinned by rising biomarker discovery pipelines and mandatory CDx co-development for novel therapeutics. However, success depends on navigating complex validation processes and ensuring scalable manufacturing.

Innovation landscape is dynamic, with next-generation sequencing (NGS), liquid biopsies, and AI-driven biomarker analytics reshaping service offerings. Early adopters are positioning for leadership in precision oncology.

Demand–supply balance reveals structural bottlenecks, as demand for rapid, cost-effective CDx development outpaces capacity, particularly in emerging markets. Strategic investments in CRO partnerships are critical to address this gap.

Key risk factors include regulatory delays, high R&D attrition rates, and reimbursement uncertainties. Fragmented reimbursement policies in key markets remain a significant barrier to widespread adoption.

11 items

1. Executive Summary

2. Companion Diagnostics (CDx) Development Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Companion Diagnostics (CDx) Development Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Companion Diagnostics (CDx) Development Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Infectious Diseases

6.1.2. Neurological Disorders

6.2. Global Companion Diagnostics (CDx) Development Services Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Feasibility Studies

6.2.2. Assay Development

6.2.3. Analytical Validation

6.2.4. Clinical Validation

6.2.5. Others

6.3. Global Companion Diagnostics (CDx) Development Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Companion Diagnostics (CDx) Development Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Companion Diagnostics (CDx) Development Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Companion Diagnostics (CDx) Development Services Market Competition by Key Manufacturers

8.1. Global Companion Diagnostics (CDx) Development Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Companion Diagnostics (CDx) Development Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Geneuity-Clinical Research Services

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Interpace Biosciences

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Labcorp

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Quest Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Q² Solutions

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ResearchDx

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Almac Diagnostic Services

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biocartis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cerba Research

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eurofins Scientific

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. MLM Medical Labs

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Qiagen

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. BGI Genomics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. MEDx Translational Medicine

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Medical Biological Laboratories (MBL)

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Novogene

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Segnment

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Companion Diagnostics (CDx) Development Services Market

Figure 4: Global Companion Diagnostics (CDx) Development Services Market: Drivers

Figure 5: Global Companion Diagnostics (CDx) Development Services Market: Challenges

Figure 6: Global Companion Diagnostics (CDx) Development Services Market: Trends

Figure 7: Global Companion Diagnostics (CDx) Development Services Market: Opportunity

Figure 8: Global Companion Diagnostics (CDx) Development Services Market: Restraint

Figure 9: Global Companion Diagnostics (CDx) Development Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Companion Diagnostics (CDx) Development Services Market Value (USD Million) By Region

Figure 15: Global Companion Diagnostics (CDx) Development Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Companion Diagnostics (CDx) Development Services Market Value (USD Million) By Region

Figure 23: Global Companion Diagnostics (CDx) Development Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Companion Diagnostics (CDx) Development Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Companion Diagnostics (CDx) Development Services Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Companion Diagnostics (CDx) Development Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Companion Diagnostics (CDx) Development Services Market Value (USD Million) By Region

Table 10: Global Companion Diagnostics (CDx) Development Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Companion Diagnostics (CDx) Development Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Companion Diagnostics (CDx) Development Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Companion Diagnostics (CDx) Development Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Geneuity-Clinical Research Services Basic Information And Sales Area

Table 31: Geneuity-Clinical Research Services. Products Portfolio

Table 32: Interpace Biosciences Basic Information And Sales Area

Table 33: Interpace Biosciences. Products Portfolio

Table 34: Labcorp Basic Information And Sales Area

Table 35: Labcorp. Products Portfolio

Table 36: Quest Diagnostics Basic Information And Sales Area

Table 37: Quest Diagnostics. Products Portfolio

Table 38: Q² Solutions Basic Information And Sales Area

Table 39: Q² Solutions. Products Portfolio

Table 40: ResearchDx Basic Information And Sales Area

Table 41: ResearchDx. Products Portfolio

Table 42: Almac Diagnostic Services Basic Information And Sales Area

Table 43: Almac Diagnostic Services. Products Portfolio

Table 44: Biocartis Basic Information And Sales Area

Table 45: Biocartis. Products Portfolio

Table 46: Cerba Research Basic Information And Sales Area

Table 47: Cerba Research. Products Portfolio

Table 48: Eurofins Scientific Basic Information And Sales Area

Table 49: Eurofins Scientific. Products Portfolio

Table 50: MLM Medical Labs Basic Information And Sales Area

Table 51: MLM Medical Labs. Products Portfolio

Table 52: Qiagen Basic Information And Sales Area

Table 53: Qiagen. Products Portfolio

Table 54: BGI Genomics Basic Information And Sales Area

Table 55: BGI Genomics. Products Portfolio

Table 56: MEDx Translational Medicine Basic Information And Sales Area

Table 57: MEDx Translational Medicine. Products Portfolio

Table 58: Medical Biological Laboratories (MBL) Basic Information And Sales Area

Table 59: Medical Biological Laboratories (MBL). Products Portfolio

Table 60: Novogene Basic Information And Sales Area

Table 61: Novogene. Products Portfolio

Table 62: Segnment Basic Information And Sales Area

Table 63: Segnment. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Companion Diagnostics (CDx) Development Services Market Value (USD Million) By Region

Table 69: Global Companion Diagnostics (CDx) Development Services Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Companion Diagnostics (CDx) Development Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.50 billion
Growth rate	CAGR of 14.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Geneuity-Clinical Research Services; Interpace Biosciences; Labcorp; Quest Diagnostics; Q² Solutions; ResearchDx; Almac Diagnostic Services; Biocartis; Cerba Research; Eurofins Scientific; MLM Medical Labs; Qiagen; BGI Genomics; MEDx Translational Medicine; Medical Biological Laboratories (MBL); Novogene; Segnment
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Companion Diagnostics (CDx) Development Services Segmentation Breakdown9 items

Application

Infectious Diseases

Neurological Disorders

Types

Feasibility Studies

Assay Development

Analytical Validation

Clinical Validation

Others

Regional Insights

Loading chart…

Competitive Landscape

Geneuity-Clinical Research Services: Regional expansion into Asia-Pacific oncology markets

Interpace Biosciences: Innovation pipeline targeting rare oncology biomarkers

Labcorp: OEM tie-ups for multiplexed CDx assay co-development

Quest Diagnostics: Vertical integration in NGS-based companion diagnostic platforms

Q² Solutions: Cost-optimized clinical trial diagnostic services for mid-tier pharma clients

ResearchDx: Localized GMP manufacturing for decentralized CDx trial logistics

Key Companion Diagnostics (CDx) Development Services Companies17 items

Geneuity-Clinical Research Services

Interpace Biosciences

Labcorp

Quest Diagnostics

Q² Solutions

ResearchDx

Almac Diagnostic Services

Biocartis

Cerba Research

Eurofins Scientific

MLM Medical Labs

Qiagen

BGI Genomics

MEDx Translational Medicine

Medical Biological Laboratories (MBL)

Novogene

Segnment

Market Ecosystem

Biotechnology firms — supply biomarker identification tools and reagents for assay design

Diagnostic developers — engineer CDx assays and platforms for targeted disease subpopulations

Pharmaceutical companies — co-develop CDx solutions alongside therapeutics for regulatory alignment

Contract research organizations — execute clinical validation studies and bioinformatics analysis

Regulatory agencies — establish approval pathways and harmonize diagnostic-drug codevelopment standards

IT solution providers — deploy digital systems for data integration and test result management

Healthcare providers — adopt CDx tools for patient stratification and treatment monitoring

Recent Industry Insights

Analyst Overview

Key Insights5 items

Table of Contents